<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="821a327e-282e-411a-9c3f-0866e90f05af"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use AZITHROMYCIN TABLETS safely and effectively. See full prescribing information for AZITHROMYCIN TABLETS.<br/>AZITHROMYCIN tablets, 600 mg, for oral use<br/>Initial U.S. Approval: 1991</title>
   <effectiveTime value="20250218"/>
   <setId root="c9990a1d-5238-403e-9221-72a9314d7b5e"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="089153071" root="1.3.6.1.4.1.519.1"/>
            <name>Lupin Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="675923163" root="1.3.6.1.4.1.519.1"/>
                  <name>LUPIN LIMITED</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="677600414" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-863" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-863" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="695c34df-8335-46bb-a69f-a41177a7e326"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250218"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68180-863" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>azithromycin<suffix/>
                        </name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>azithromycin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="600" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5FD1131I7S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AZITHROMYCIN DIHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J2KLZ20U1M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AZITHROMYCIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68180-863-06" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43186" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CONTAINER"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20221117"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA065400" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20221117"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="19" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">LU;L06</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID697">
               <id root="21068323-026b-4b03-8cc5-265850c420cd"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID699">Warnings and Precautions, Cardiovascular Death (<linkHtml href="#ID563">5.5</linkHtml>)                        11/2021</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID522">
               <id root="77f8478d-0c6c-478f-b7bd-01ad9087bf22"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID530">Azithromycin tablets are a macrolide antibacterial indicated for mild to moderate infections caused by designated, susceptible bacteria: </paragraph>
                        <list listType="unordered" ID="ID531" styleCode="Disc">
                           <item>Mycobacterial Infections (<linkHtml href="#ID527">1.2</linkHtml>)</item>
                        </list>
                        <paragraph ID="ID532">To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs, azithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (<linkHtml href="#ID691">1.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID682">
                     <id root="d4563d60-c95c-4a98-af58-1d437f893afd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID683">Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID527">
                     <id root="025af5a7-9095-4960-8620-908e891c7d65"/>
                     <title>1.2 Mycobacterial Infections</title>
                     <text>
                        <paragraph ID="ID528">
                           <content styleCode="bold">
                              <content styleCode="italics">Prophylaxis of Disseminated Mycobacterium avium complex (MAC) Disease </content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin tablets, taken alone or in combination with rifabutin at its approved dose, are indicated for the prevention of disseminated MAC disease in persons with advanced HIV infection <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID533">2</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Treatment of Disseminated MAC Disease </content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin tablets, taken in combination with ethambutol, are indicated for the treatment of disseminated MAC infections in persons with advanced HIV infection <content styleCode="italics">[see USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID598">8.4</linkHtml>) and CLINICAL STUDIES (<linkHtml href="#ID637">14.1</linkHtml>)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID691">
                     <id root="0300a091-0af8-444c-9d50-fa40068db1e1"/>
                     <title>1.3 Usage</title>
                     <text>
                        <paragraph ID="ID692">To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs, azithromycin tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID533">
               <id root="27055a58-2be6-4161-a5b5-eb0ccfea8c56"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID541" styleCode="Disc">
                           <item>Mycobacterial Infections (<linkHtml href="#ID538">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID684">
                     <id root="c42a95c1-0e32-44a5-a829-5b03387db3ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID685">
                           <content styleCode="italics">[see INDICATIONS AND USAGE (<linkHtml href="#ID522">1</linkHtml>)] </content>
                        </paragraph>
                        <paragraph>Azithromycin tablets can be taken with or without food. However, increased tolerability has been observed when tablets are taken with food. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID538">
                     <id root="98b189c6-d7f9-4906-8294-5a3ba7a88e5c"/>
                     <title>2.2 Mycobacterial Infections</title>
                     <text>
                        <paragraph ID="ID539">
                           <content styleCode="bold">
                              <content styleCode="italics">Prevention of Disseminated MAC Infections </content>
                           </content>
                        </paragraph>
                        <paragraph>The recommended dose of azithromycin for the prevention of disseminated <content styleCode="italics">Mycobacterium avium </content>complex (MAC) disease is: 1200 mg taken once weekly. This dose of azithromycin may be combined with the approved dosage regimen of rifabutin. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Treatment of Disseminated MAC Infections </content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin should be taken at a daily dose of 600 mg, in combination with ethambutol at the recommended daily dose of 15 mg/kg. Other antimycobacterial drugs that have shown <content styleCode="italics">in vitro </content>activity against MAC may be added to the regimen of azithromycin plus ethambutol at the discretion of the physician or health care provider. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID542">
               <id root="7151e258-b4cc-4df0-98d6-347fc2759f2d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID546" styleCode="Disc">
                           <item>Azithromycin tablets USP, 600 mg (<linkHtml href="#ID542">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID686">
                     <id root="b3bdd0ae-d40f-4f84-a58b-b5bf6b6e3b85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID687">Azithromycin Tablets USP, 600 mg are supplied as white, oval shaped film-coated tablets, engraved with "LU" on one side and "L06" on the other side containing azithromycin dihydrate equivalent to 600 mg of azithromycin USP. These are packaged in bottles of 30 tablets.</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID547">
               <id root="76683fa6-c83f-464c-93ad-f1697de5ce74"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID553" styleCode="Disc">
                           <item>Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide antibiotic. (<linkHtml href="#ID548">4.1</linkHtml>)</item>
                           <item>Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. (<linkHtml href="#ID550">4.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID548">
                     <id root="5a870637-268f-4ede-9245-81cc0562376c"/>
                     <title>4.1 Hypersensitivity</title>
                     <text>
                        <paragraph ID="ID549">Azithromycin is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide drug. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID550">
                     <id root="200e108e-0f0d-4b97-a2f2-e0c5de7fc1bf"/>
                     <title>4.2 Hepatic Dysfunction</title>
                     <text>
                        <paragraph ID="ID551">Azithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID554">
               <id root="b0a300af-9fdd-4154-9473-c3dc0ae6d138"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID572" styleCode="Disc">
                           <item>Serious (including fatal) allergic and skin reactions. Discontinue azithromycin and initiate appropriate therapy if reaction occurs. (<linkHtml href="#ID555">5.1</linkHtml>)</item>
                           <item>Hepatotoxicity: Discontinue azithromycin immediately if signs and symptoms of hepatitis occur. (<linkHtml href="#ID557">5.2</linkHtml>)</item>
                           <item>Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. (<linkHtml href="#ID693">5.3</linkHtml>)</item>
                           <item>Prolongation of QT interval and cases of torsades de pointes have been reported. This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (<linkHtml href="#ID559">5.4</linkHtml>)</item>
                           <item>Cardiovascular Death: Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. Consider balancing this potential risk with treatment benefits when prescribing azithromycin tablets. (<linkHtml href="#ID563">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Clostridium difficile</content> -Associated Diarrhea: Evaluate patients if diarrhea occurs. (<linkHtml href="#ID700">5.6</linkHtml>)</item>
                           <item>Azithromycin exacerbate muscle weakness in persons with myasthenia gravis (<linkHtml href="#ID565">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID555">
                     <id root="5517f494-5e06-415d-9692-e97946b4a470"/>
                     <title>5.1 Hypersensitivity</title>
                     <text>
                        <paragraph ID="ID556">Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens-Johnson Syndrome, and toxic epidermal necrolysis, have been reported rarely in patients on azithromycin therapy. <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID548">4.1</linkHtml>)]</content>
                        </paragraph>
                        <paragraph ID="ID689">Fatalities have been reported. Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported. Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure<content styleCode="bold">. </content>These patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is presently unknown. </paragraph>
                        <paragraph ID="ID690">If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that allergic symptoms may reappear when symptomatic therapy is discontinued. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID557">
                     <id root="3b3e03df-b28d-4b60-9a78-7a9949636f57"/>
                     <title>5.2 Hepatotoxicity</title>
                     <text>
                        <paragraph ID="ID558">Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID693">
                     <id root="d391addf-7782-471d-a744-53a16b25adcb"/>
                     <title>5.3 Infantile Hypertrophic Pyloric Stenosis</title>
                     <text>
                        <paragraph ID="ID694">Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs.</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID559">
                     <id root="004d2f59-62c4-4976-8bb5-ed671e8decc3"/>
                     <title>5.4 QT Prolongation</title>
                     <text>
                        <paragraph ID="ID560">Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen with treatment with macrolides, including azithromycin. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving azithromycin. Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including: </paragraph>
                        <list listType="unordered" ID="ID561" styleCode="Disc">
                           <item>patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure</item>
                           <item>patients on drugs known to prolong the QT interval</item>
                           <item>patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.</item>
                        </list>
                        <paragraph ID="ID562">Elderly patients may be more susceptible to drug-associated effects on the QT interval. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID563">
                     <id root="94bca27c-a37a-4274-b11a-16496fd6eecd"/>
                     <title>
                        <content styleCode="xmChange">5.5 Cardiovascular Death</content>
                     </title>
                     <text>
                        <paragraph ID="ID564">
                           <content styleCode="xmChange">
Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. The five-day cardiovascular mortality observed in these studies ranged from 20 to 400 per million azithromycin treatment courses. This potential risk was noted to be greater during the first five days of azithromycin use and does not appear to be limited to those patients with preexisting cardiovascular diseases. The data in these observational studies are insufficient to establish or exclude a causal relationship between acute cardiovascular death and azithromycin use. Consider balancing this potential risk with treatment benefits when prescribing azithromycin tablets.<br/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID700">
                     <id root="f541ad69-92ca-4d3e-aa64-730305f2b2ab"/>
                     <title>5.6 Clostridium difficile-Associated Diarrhea (CDAD)</title>
                     <text>
                        <paragraph ID="ID701">CDAD has been reported with use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of <content styleCode="italics">C. difficile</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B which contribute to the development of CDAD. Hypertoxin<content styleCode="bold">-</content>producing strains of <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID565">
                     <id root="ef5e5100-6251-41a4-b976-d19a4b4be0f6"/>
                     <title>5.7 Exacerbation of Myasthenia Gravis</title>
                     <text>
                        <paragraph ID="ID566">Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID569">
                     <id root="731fc9cb-f970-49d8-b3b7-08c7ad5737b0"/>
                     <title>5.8 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph ID="ID570">Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID573">
               <id root="b231eab0-7b25-4549-8827-eb5987f09767"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID695">The following clinically significant adverse reactions are described elsewhere in labeling:</paragraph>
                  <list listType="unordered" ID="ID696" styleCode="Disc">
                     <item>Hypersensitivity <content styleCode="italics">[see WARNINGS AND PRECAUTIONS</content>
                        <content styleCode="italics">(<linkHtml href="#ID555">5.1</linkHtml>)]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see WARNINGS AND PRECAUTIONS</content>
                        <content styleCode="italics">(<linkHtml href="#ID557">5.2</linkHtml>)]</content>
                     </item>
                     <item>Infantile Hypertrophic Pyloric Stenosis (IHPS) <content styleCode="italics">[see WARNINGS AND PRECAUTIONS</content>
                        <content styleCode="italics">(<linkHtml href="#ID693">5.3</linkHtml>)]</content>
                     </item>
                     <item>QT Prolongation <content styleCode="italics">[see WARNINGS AND PRECAUTIONS</content>
                        <content styleCode="italics">(<linkHtml href="#ID559">5.4</linkHtml>)]</content>
                     </item>
                     <item>Cardiovascular Death <content styleCode="italics">[see WARNINGS AND PRECAUTIONS</content>
                        <content styleCode="italics">(<linkHtml href="#ID563">5.5</linkHtml>)]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Clostridiodes difficile-</content> Associated Diarrhea (CDAD) <content styleCode="italics">[see WARNINGS AND PRECAUTIONS</content>
                        <content styleCode="italics">(<linkHtml href="#ID700">5.6</linkHtml>)]</content>
                     </item>
                     <item>Exacerbation of Myasthenia Gravis <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID565">5.7</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID583">The most common adverse reactions are diarrhea (5%), nausea (3%), abdominal pain (3%), or vomiting, (no percent given) (<linkHtml href="#ID573">6</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID574">
                     <id root="80179073-3f9b-4d61-a801-7451640452b9"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID575">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>In clinical trials, most of the reported adverse reactions were mild to moderate in severity and were reversible upon discontinuation of the drug. Approximately 0.7% of the patients from the multiple-dose clinical trials discontinued azithromycin therapy because of treatment-related adverse reactions. Serious adverse reactions included angioedema and cholestatic jaundice. Most of the adverse reactions leading to discontinuation were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. <content styleCode="italics">[see CLINICAL STUDIES (<linkHtml href="#ID636">14.2</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Multiple-dose regimen</content> </content>
                        </paragraph>
                        <paragraph>Overall, the most common adverse reactions in adult patients receiving a multiple-dose regimen of azithromycin were related to the gastrointestinal system with diarrhea/loose stools (5%), nausea (3%), and abdominal pain (3%) being the most frequently reported. </paragraph>
                        <paragraph>No other adverse reactions occurred in patients on the multiple-dose regimen of azithromycin with a frequency greater than 1%. Adverse reactions that occurred with a frequency of 1% or less included the following: </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular: </content>
                           </content>
                        </paragraph>
                        <paragraph>Palpitations and chest pain. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gastrointestinal: </content>
                           </content>
                        </paragraph>
                        <paragraph>Dyspepsia, flatulence, vomiting, melena, and cholestatic jaundice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Genitourinary: </content>
                           </content>
                        </paragraph>
                        <paragraph>Monilia, vaginitis, and nephritis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Nervous System: </content>
                           </content>
                        </paragraph>
                        <paragraph>Dizziness, headache, vertigo, and somnolence.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">General: </content>
                           </content>
                        </paragraph>
                        <paragraph>Fatigue.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Allergic: </content>
                           </content>
                        </paragraph>
                        <paragraph>Rash, photosensitivity, and angioedema. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Chronic therapy with 1200 mg weekly regimen</content>
                           </content>
                        </paragraph>
                        <paragraph>The nature of adverse reactions seen with the 1200 mg weekly dosing regimen for the prevention of <content styleCode="italics">Mycobacterium avium </content>infection in severely immunocompromised HIV-infected patients were similar to those seen with short-term dosing regimens. <content styleCode="italics">[see CLINICAL STUDIES (<linkHtml href="#ID636">14</linkHtml>)]</content> </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Chronic therapy with 600 mg daily regimen combined with ethambutol</content> </content>
                        </paragraph>
                        <paragraph>The nature of adverse reactions seen with the 600 mg daily dosing regimen for the treatment of <content styleCode="italics">Mycobacterium avium </content>complex infection in severely immunocompromised HIV-infected patients were similar to those seen with short term dosing regimens. Five percent of patients experienced reversible hearing impairment in the pivotal clinical trial for the treatment of disseminated MAC in patients with AIDS.  Hearing impairment has been reported with macrolide antibiotics, especially at higher doses. Other treatment-related adverse reactions occurring in &gt;5% of subjects and seen at any time during a median of 87.5 days of therapy include: abdominal pain (14%), nausea (14%), vomiting (13%), diarrhea (12%), flatulence (5%), headache (5%), and abnormal vision (5%). Discontinuations from treatment due to laboratory abnormalities or adverse reactions considered related to study drug occurred in 8 of 88 (9.1%) of subjects. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID576">
                     <id root="e2a45335-96c0-4e59-9a8b-f77ac1572e53"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID577">The following adverse reactions have been identified during post approval use of azithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>Adverse reactions reported with azithromycin during the postmarketing period in adult and/or pediatric patients for which a causal relationship may not be established include:</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Allergic</content>
                           </content>
                        </paragraph>
                        <paragraph>Arthralgia, edema, urticaria, and angioedema.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular</content>
                           </content>
                        </paragraph>
                        <paragraph>Arrhythmias, including ventricular tachycardia, and hypotension. There have been reports of QT prolongation and <content styleCode="italics">torsades de pointes, </content>and cardiovascular death.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gastrointestinal</content>
                           </content>
                        </paragraph>
                        <paragraph>Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea pseudomembranous colitis, pancreatitis, oral candidiasis, pyloric stenosis, and tongue discoloration.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">General</content>
                           </content>
                        </paragraph>
                        <paragraph>Asthenia, paresthesia, fatigue, malaise, and anaphylaxis</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Genitourinary</content>
                           </content>
                        </paragraph>
                        <paragraph>Interstitial nephritis, acute renal failure, and vaginitis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hematopoietic</content>
                           </content>
                        </paragraph>
                        <paragraph>Thrombocytopenia.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Liver/Biliary</content>
                           </content>
                        </paragraph>
                        <paragraph>Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure. <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID557">5.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Nervous System</content>
                           </content>
                        </paragraph>
                        <paragraph>Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity, nervousness, agitation, and syncope.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Psychiatric</content>
                           </content>
                        </paragraph>
                        <paragraph>Aggressive reaction and anxiety.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Skin/Appendages</content>
                           </content>
                        </paragraph>
                        <paragraph>Pruritus, and serious skin reactions including erythema multiforme, AGEP, Stevens-Johnson Syndrome, toxic epidermal necrolysis, and DRESS.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Special Senses</content>
                           </content>
                        </paragraph>
                        <paragraph>Hearing disturbances including hearing loss, deafness, and/or tinnitus, and reports of taste/smell perversion and/or loss. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID578">
                     <id root="cc21b867-42a1-4df1-9caa-11e734bfe87a"/>
                     <title>6.3 Laboratory Abnormalities</title>
                     <text>
                        <paragraph ID="ID579">Significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows: </paragraph>
                        <list listType="unordered" ID="ID580" styleCode="Disc">
                           <item>With an incidence of 1 to 2%, elevated serum creatine phosphokinase, potassium, ALT (SGPT), GGT, and AST (SGOT).</item>
                           <item>With an incidence of less than 1%, leukopenia, neutropenia, decreased platelet count, elevated serum alkaline phosphatase, bilirubin, BUN, creatinine, blood glucose, LDH, and phosphate.</item>
                        </list>
                        <paragraph ID="ID581">When follow-up was provided, changes in laboratory tests appeared to be reversible. </paragraph>
                        <paragraph>In multiple-dose clinical trials involving more than 3000 patients, 3 patients discontinued therapy because of treatment-related liver enzyme abnormalities and 1 because of a renal function abnormality. </paragraph>
                        <paragraph>In a phase 1 drug interaction study performed in normal volunteers, 1 of 6 subjects given the combination of azithromycin and rifabutin, 1 of 7 given rifabutin alone, and 0 of 6 given azithromycin alone developed a clinically significant neutropenia (&lt;500 cells/mm<sup>3</sup>). </paragraph>
                        <paragraph>Laboratory abnormalities seen in clinical trials for the prevention of disseminated <content styleCode="italics">Mycobacterium avium </content>disease in severely immunocompromised HIV-infected patients. <content styleCode="italics">[see CLINICAL STUDIES (<linkHtml href="#ID636">14</linkHtml>)] </content>
                        </paragraph>
                        <paragraph>Chronic therapy (median duration: 87.5 days, range: 1 to 229 days) that resulted in laboratory abnormalities in &gt;5% of subjects with normal baseline values in the pivotal trial for treatment of disseminated MAC in severely immunocompromised HIV<content styleCode="bold">-</content>infected patients treated with azithromycin 600 mg daily in combination with ethambutol include: a reduction in absolute neutrophils to &lt;50% of the lower limit of normal (10/52, 19%) and an increase to five times the upper limit of normal in alkaline phosphatase (3/35, 9%). These findings in subjects with normal baseline values are similar when compared to all subjects for analyses of neutrophil reductions (22/75, 29%) and elevated alkaline phosphatase (16/80, 20%). Causality of these laboratory abnormalities due to the use of study drug has not been established. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID584">
               <id root="1e08a116-472c-4a83-9950-7bd12139ffae"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID592" styleCode="Disc">
                           <item>Nelfinavir: Close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (<linkHtml href="#ID585">7.1</linkHtml>)</item>
                           <item>Warfarin: Use with azithromycin may increase coagulation times; monitor prothrombin time. (<linkHtml href="#ID587">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID585">
                     <id root="10b4a0da-0c94-460f-8174-a72615e68455"/>
                     <title>7.1 Nelfinavir</title>
                     <text>
                        <paragraph ID="ID586">Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. <content styleCode="italics">[see ADVERSE REACTIONS (<linkHtml href="#ID573">6</linkHtml>)] </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID587">
                     <id root="732e078b-fb78-4d71-861f-3c0fe7d7a604"/>
                     <title>7.2 Warfarin</title>
                     <text>
                        <paragraph ID="ID588">Spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants such as warfarin, although the prothrombin time was not affected in the dedicated drug interaction study with azithromycin and warfarin.  Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID589">
                     <id root="d25690f4-b104-469e-9d25-4183503c68ca"/>
                     <title>7.3 Potential Drug-Drug Interaction with Macrolides</title>
                     <text>
                        <paragraph ID="ID590">Interactions digoxin, colchicine or phenytoin have not been reported in clinical trials with azithromycin. No specific drug interaction studies have been performed to evaluate potential drug-drug interaction. However, drug interactions have been observed with other macrolide products. Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID593">
               <id root="0b49f941-9451-4117-aa0b-5124c1f04a70"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20221117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID603" styleCode="Disc">
                           <item>Pediatric Use: Safety and effectiveness in the treatment of patients under 6 months of age have not been established. (<linkHtml href="#ID598">8.4</linkHtml>)</item>
                           <item>Geriatric Use: Elderly patients may be more susceptible to development of torsades de pointes arrhythmias. (<linkHtml href="#ID600">8.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID594">
                     <id root="47d869b2-02bc-4dd1-a4d8-8a4919ad02c7"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID595">
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary </content>
                           </content>
                        </paragraph>
                        <paragraph>Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes <content styleCode="italics">(see Data)</content>.</paragraph>
                        <paragraph>Developmental toxicity studies with azithromycin in rats, mice, and rabbits showed no drug-induced fetal malformations at doses up to 3, 2, and 1 times, respectively, an adult human daily dose of 600 mg based on body surface area. Decreased viability and delayed development were observed in the offspring of pregnant rats administered azithromycin from day 6 of pregnancy through weaning at a dose equivalent to 3 times an adult human daily dose of 600 mg based on body surface area <content styleCode="italics">(see Data).</content>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Data</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Human Data:</content>
                           </content>
                        </paragraph>
                        <paragraph>Available data from published observational studies, case series, and case reports over several decades do not suggest an increased risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with azithromycin use in pregnant women. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying maternal disease and maternal use of concomitant medications.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Animal Data:</content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin administered during the period of organogenesis did not cause fetal malformations in rats and mice at oral doses up to 200 mg/kg/day (moderately maternally toxic). Based on body surface area, this dose is approximately 3 (rats) and 2 (mice) times an adult human daily dose of 600 mg. In rabbits administered azithromycin at oral doses of 10, 20, and 40 mg/kg/day during organogenesis, reduced maternal body weight and food consumption were observed in all groups; no evidence of fetotoxicity or teratogenicity was observed at these doses, the highest of which is approximately equal to an adult human daily dose of 600 mg based on body surface area.</paragraph>
                        <paragraph>In a pre-and postnatal development study, azithromycin was administered orally to pregnant rats from day 6 of pregnancy until weaning at doses of 50 or 200 mg/kg/day. Maternal toxicity (reduced food consumption and body weight gain; increased stress at parturition) was observed at the higher dose. Effects in the offspring were noted at 200 mg/kg/day during the postnatal development period (decreased viability, delayed developmental landmarks). These effects were not observed in a pre-and postnatal rat study when up to 200 mg/kg/day of azithromycin was given orally beginning on day 15 of pregnancy until weaning.</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID596">
                     <id root="a4cbea36-1078-439f-9717-184c3892418d"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID597">
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary </content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin is present in human milk <content styleCode="italics">(see Data)</content>. Non-serious adverse reactions have been reported in breastfed infants after maternal administration of azithromycin <content styleCode="italics">(see Clinical Considerations)</content>. There are no available data on the effects of azithromycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for azithromycin and any potential adverse effects on the breastfed infant from azithromycin or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Clinical Considerations</content>
                           </content>
                        </paragraph>
                        <paragraph>Advise women to monitor the breastfed infant for diarrhea, vomiting, or rash.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Data </content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin breastmilk concentrations were measured in 20 women after receiving a single 2 g oral dose of azithromycin during labor. Breastmilk samples collected on days 3 and 6 postpartum as well as 2 and 4 weeks postpartum revealed the presence of azithromycin in breastmilk up to 4 weeks after dosing. In another study, a single dose of azithromycin 500 mg was administered intravenously to 8 women prior to incision for cesarean section. Breastmilk (colostrum) samples obtained between 12 and 48 hours after dosing revealed that azithromycin persisted in breastmilk up to 48 hours.</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID598">
                     <id root="4e285b6b-2f9f-4f74-84c2-c1f03a2bea5b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID599">In controlled clinical studies, azithromycin has been administered to pediatric patients ranging in age from 6 months to 12 years. For information regarding the use of azithromycin for oral suspension in the treatment of pediatric patients, <content styleCode="italics">[see INDICATIONS AND USAGE (<linkHtml href="#ID522">1</linkHtml>) </content>and <content styleCode="italics">DOSAGE AND ADMINISTRATION (<linkHtml href="#ID533">2</linkHtml>)] </content>of the prescribing information for azithromycin for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">HIV-Infected Pediatric Patients</content>
                           </content> </paragraph>
                        <paragraph>The safety and efficacy of azithromycin for the prevention or treatment of MAC in HIV-infected children have not been established. Safety data are available for 72 children 5 months to 18 years of age (mean 7 years) who received azithromycin for treatment of opportunistic infections. The mean duration of therapy was 242 days (range 3 to 2004 days) at doses of &lt;1 to 52 mg/kg/day (mean 12 mg/kg/day). Adverse reactions were similar to those observed in the adult population, most of which involved the gastrointestinal tract. Treatment<content styleCode="bold">-</content>related reversible hearing impairment in children was observed in 4 subjects (5.6%). Two (2.8%) children prematurely discontinued treatment due to adverse reactions: one due to back pain and one due to abdominal pain, hot and cold flushes, dizziness, headache, and numbness. A third child discontinued due to a laboratory abnormality (eosinophilia). The protocols upon which these data are based specified a daily dose of 10 to 20 mg/kg/day (oral and/or IV) of azithromycin. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID600">
                     <id root="1be1d520-f604-419c-8af7-9aae5120376a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID601">In multiple-dose clinical trials of oral azithromycin, 9% of patients were at least 65 years of age (458/4949) and 3% of patients (144/4949) were at least 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. </paragraph>
                        <paragraph>Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients. <content styleCode="italics">[see</content> <content styleCode="italics">WARNINGS AND PRECAUTIONS (<linkHtml href="#ID559">5.4</linkHtml>)]</content> </paragraph>
                        <paragraph>Azithromycin 600 mg tablets contain 1.5 mg of sodium per tablet. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Geriatric Patients with Opportunistic Infections, Including (MAC) Disease</content>
                           </content>
                        </paragraph>
                        <paragraph>Safety data are available for 30 patients (65 to 94 years old) treated with azithromycin at doses &gt;300 mg/day for a mean of 207 days. These patients were treated for a variety of opportunistic infections, including MAC. The adverse reaction were generally similar to that seen in younger patients, except for a higher incidence of adverse reactions relating to the gastrointestinal system and to reversible impairment of hearing. <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID533">2</linkHtml>)] </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID604">
               <id root="684eccc6-02cc-4fe3-a8cb-f9d80f4340b1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20221117"/>
               <component>
                  <section ID="ID679">
                     <id root="1542d955-e1a0-41ec-98b4-f2f55f5182d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID605">Adverse reactions experienced in higher than recommended doses were similar to those seen at normal doses. In the event of overdosage, general symptomatic and supportive measures are indicated as required. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID606">
               <id root="43316378-0d19-4b9c-b9f4-8d059f4e4833"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <effectiveTime value="20250218"/>
               <component>
                  <section ID="ID680">
                     <id root="dc61c21c-e8b5-4a1d-a687-dbd1ce7b00ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID607">Azithromycin tablets USP contain the active ingredient azithromycin, a macrolide antibacterial drug, for oral administration. Azithromycin has the chemical name (<content styleCode="italics">2R,3S,4R,5R,8R,10R,11R,12S,13S,14R</content>)-13-[(2,6-dideoxy-3-<content styleCode="italics">C</content>-methyl-3-<content styleCode="italics">O</content>-methyl-α<content styleCode="italics">-L-ribo</content>-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-<content styleCode="italics">D-xylo</content>-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring. Its molecular formula is C<sub>38</sub>H<sub>72</sub>N<sub>2</sub>O<sub>12</sub>, and its molecular weight is 749.0. Azithromycin has the following structural formula:</paragraph>
                        <renderMultiMedia referencedObject="MM1"/>
                        <paragraph ID="ID609">Azithromycin, as the dihydrate, is a white to almost white crystalline powder with a molecular formula of C<sub>38</sub>H<sub>72</sub>N<sub>2</sub>O<sub>12</sub>•2H<sub>2</sub>O and a molecular weight of 785.02</paragraph>
                        <paragraph>Azithromycin tablets USP contain azithromycin dihydrate equivalent to 600 mg azithromycin. They also contain the following inactive ingredients: croscarmellose sodium, dibasic calcium phosphate, hydroxypropyl methyl cellulose, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, titanium dioxide and triacetin.</paragraph>
                        <paragraph>Organic Impurities Test Pending.</paragraph>
                     </text>
                     <effectiveTime value="20250218"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM1">
                     <text>Sturcture</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="821a327e-282e-411a-9c3f-0866e90f05af-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID610">
               <id root="3524c1b6-0547-4ab2-b5fc-6d6c0a72f756"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20221117"/>
               <component>
                  <section ID="ID611">
                     <id root="f16aed63-b323-4215-80f5-3b5b4ee5ff9a"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID612">Azithromycin is a macrolide antibacterial drug. <content styleCode="italics">[see Microbiology (<linkHtml href="#ID621">12.4</linkHtml>)] </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID613">
                     <id root="96932575-7ed7-4504-9705-86eb7d607d2a"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID614">Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with the ratio of area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) for certain pathogens (<content styleCode="italics">S. pneumoniae </content>and <content styleCode="italics">S. aureus</content>). The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with azithromycin. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiac Electrophysiology </content>
                           </content>
                        </paragraph>
                        <paragraph>QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1000 mg) alone or in combination with oral azithromycin (500 mg, 1000 mg, and 1500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose-and concentration-dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID615">
                     <id root="8bab3a85-0035-4e8d-af88-e49861ef97e9"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID616">The pharmacokinetic parameters of azithromycin in plasma after dosing as per labeled recommendations in healthy young adults and asymptomatic HIV-positive adults (age 18 to 40 years old) are portrayed in the following chart: </paragraph>
                        <table ID="ID664" width="0" styleCode="Noautorules">
                           <caption>  MEAN (CV%) PK PARAMETER </caption>
                           <col width="109"/>
                           <col width="62"/>
                           <col width="38"/>
                           <col width="71"/>
                           <col width="44"/>
                           <col width="71"/>
                           <col width="111"/>
                           <col width="50"/>
                           <col width="71"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> DOSE/DOSAGE FORM (serum, except as indicated)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Subjects</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Day No.</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> C<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (mcg/mL)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> T<sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (hr)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> C<sub>24 </sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (mcg/mL)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> AUC (mcg</content> •<content styleCode="bold"> hr/mL)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> T<sub>½</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold"> (hr)</content>
                                    <br/>
                                 </td>
                                 <td styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Urinary Excretion (% of dose)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> 500 mg/250 mg capsule<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.41<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2.5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.05<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2.6<footnote ID="ID6640">AUC<sub>0 to 24</sub>; <sup>b</sup>0-last. </footnote>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> –<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> and 250 mg on Days 2 to 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.24<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 3.2<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.05<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2.1<footnoteRef IDREF="ID6640"/>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> –<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> 1200 mg/600 mg tablets<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 12<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.66<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2.5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.074<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 6.8<footnote>1</footnote>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 40<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> –<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> %CV<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center"> (62%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (79%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (49%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (64%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (33%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> 600 mg tablet/day<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.33<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2.0<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.039<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2.4<footnoteRef IDREF="ID6640"/>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> %CV<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center"> 25%<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (50%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (36%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (19%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center"> 7<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 22<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.55<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 2.1<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 0.14<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 5.8<footnoteRef IDREF="ID6640"/>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 84.5<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> -<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> %CV<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center"> (18%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (52%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (26%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (25%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center"> -<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> 600 mg tablet/day (leukocytes)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 7<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 22<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 252<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 10.9<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 146<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 4763<footnoteRef IDREF="ID6640"/>
                                    <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> 82.8<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> -<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> %CV<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule"/>
                                 <td styleCode=" Botrule Rrule" align="center"> (49%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (28%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (33%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> (42%)<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> -<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> -<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID618">With a regimen of 500 mg on Day 1 and 250 mg/day on Days 2 to 5, C<sub>min</sub> and C<sub>max</sub> remained essentially unchanged from Day 2 through Day 5 of therapy. However, without a loading dose, azithromycin C<sub>min</sub> levels required 5 to 7 days to reach steady state. </paragraph>
                        <paragraph>In asymptomatic HIV-positive adult subjects receiving 600 mg azithromycin tablets once daily for 22 days, steady state azithromycin serum levels were achieved by Day 15 of dosing. </paragraph>
                        <paragraph>The high values in adults for apparent steady-state volume of distribution (31.1 L/kg) and plasma clearance (630 mL/min) suggest that the prolonged half-life is due to extensive uptake and subsequent release of drug from tissues. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption </content>
                           </content>
                        </paragraph>
                        <paragraph>The 1 gram single<content styleCode="bold">-</content>dose packet is bioequivalent to four 250 mg azithromycin capsule. </paragraph>
                        <paragraph>When the oral suspension of azithromycin was administered with food, the C<sub>max</sub> increased by 46% and the AUC by 14%. </paragraph>
                        <paragraph>The absolute bioavailability of two 600 mg tablets was 34% (CV=56%). Administration of two 600 mg tablets with food increased C<sub>max</sub> by 31% (CV=43%) while the extent of absorption (AUC) was unchanged (mean ratio of AUCs=1.00; CV=55%). </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution </content>
                           </content>
                        </paragraph>
                        <paragraph>The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL. </paragraph>
                        <paragraph>The antibacterial activity of azithromycin is pH related and appears to be reduced with decreasing pH. However, the extensive distribution of drug to tissues may be relevant to clinical activity. </paragraph>
                        <paragraph>Azithromycin has been shown to penetrate into tissues in humans, including skin, lung, tonsil, and cervix. Extensive tissue distribution was confirmed by examination of additional tissues and fluids (bone, ejaculum, prostate, ovary, uterus, salpinx, stomach, liver, and gallbladder). As there are no data from adequate and well-controlled studies of azithromycin treatment of infections in these additional body sites, the clinical importance of these tissue concentration data is unknown. </paragraph>
                        <paragraph>Azithromycin concentrates in phagocytes and fibroblasts as demonstrated by <content styleCode="italics">in vitro </content>incubation techniques. Using such methodology, the ratio of intracellular to extracellular concentration was &gt;30 after one hr of incubation. <content styleCode="italics">In vivo </content>studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues. Following oral administration of a single 1200 mg dose (two 600 mg tablets), the mean maximum concentration in peripheral leukocytes was 140 mcg/mL. Concentration remained above 32 mcg/mL, for approximately 60 hr. The mean half-lives for 6 males and 6 females were 34 hr and 57 hr, respectively. Leukocyte-to-plasma C<sub>max</sub> ratios for males and females were 258 (±77%) and 175 (±60%), respectively, and the AUC ratios were 804 (±31%) and 541 (±28%) respectively. The clinical relevance of these findings is unknown. </paragraph>
                        <paragraph>Following oral administration of multiple daily doses of 600 mg (1 tablet/day) to asymptomatic HIV-positive adults, mean maximum concentration in peripheral leukocytes was 252 mcg/mL (±49%).  Trough concentrations in peripheral leukocytes at steady-state averaged 146 mcg/mL (±33%). The mean leukocyte-to-serum C<sub>max</sub> ratio was 456 (±38%) and the mean leukocyte to serum AUC ratio was 816 (±31%). The clinical relevance of these findings is unknown. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro </content>and <content styleCode="italics">in vivo </content>studies to assess the metabolism of azithromycin have not been performed. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Elimination </content>
                           </content>
                        </paragraph>
                        <paragraph>Plasma concentrations of azithromycin following single 500 mg oral and IV doses declined in a polyphasic pattern resulting in an average terminal half-life of 68 hr. Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination. Over the course of a week, approximately 6% of the administered dose appears as unchanged drug in urine. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Specific Populations </content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Patients with Renal Impairment: </content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin pharmacokinetics was investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1.0 g dose of azithromycin (4 × 250 mg capsules), the mean C<sub>max </sub>and AUC<sub>0 to 120</sub> increased by 5.1% and 4.2%, respectively, in subjects with GFR 10 to 80 mL/min compared to subjects with normal renal function (GFR &gt;80 mL/min). The mean C<sub>max</sub> and AUC<sub>0 to 120</sub> increased 61% and 35%, respectively, in subjects with end-stage renal disease (GFR &lt;10 mL/min) compared to subjects with normal renal function (GFR &gt;80 mL/min<content styleCode="italics">). </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Patients with Hepatic Impairment:</content>
                           </content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Male and Female Patients: </content>
                           </content>
                           <content styleCode="italics"> </content>
                        </paragraph>
                        <paragraph>There are no significant differences in the disposition of azithromycin between male and female subjects.  No dosage adjustment is recommended on the basis of gender. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Geriatric Patients</content>
                           </content>
                           <content styleCode="italics">: </content>
                        </paragraph>
                        <paragraph>Pharmacokinetic parameters in older volunteers (65 to 85 years old) were similar to those in younger volunteers (18 to 40 years old) for the 5-day therapeutic regimen. Dosage adjustment does not appear to be necessary for older patients with normal renal and hepatic function receiving treatment with this dosage regimen. <content styleCode="italics">[see Geriatric Use (<linkHtml href="#ID600">8.5</linkHtml>)] </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pediatric Patients: </content>
                           </content>
                        </paragraph>
                        <paragraph>For information regarding the pharmacokinetics of azithromycin for oral suspension in pediatric patients, see the prescribing information for azithromycin for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Drug Interaction Studies:</content>
                           </content>
                        </paragraph>
                        <paragraph>Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered.  The effects of co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 1 and the effects of other drugs on the pharmacokinetics of azithromycin are shown in Table 2. </paragraph>
                        <paragraph>Co-administration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in Table 1. No dosage adjustment of drugs listed in Table 1 is recommended when co-administered with azithromycin. </paragraph>
                        <paragraph>Co-administration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C<sub>max</sub> and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in Table 2. <content styleCode="italics">[see DRUG INTERACTIONS (<linkHtml href="#ID589">7.3</linkHtml>)] </content>
                        </paragraph>
                        <table ID="ID665" width="100%">
                           <caption>Table 1: Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Azithromycin</caption>
                           <col width="18%"/>
                           <col width="23%"/>
                           <col width="22%"/>
                           <col width="8%"/>
                           <col width="15%"/>
                           <col width="14%"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Co</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">administered </content>
                                    <content styleCode="bold">Drug</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Dose </content>
                                    <content styleCode="bold">of </content>
                                    <content styleCode="bold">Co</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">administered </content>
                                    <content styleCode="bold">Drug</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Dose </content>
                                    <content styleCode="bold">of </content>
                                    <content styleCode="bold">Azithromycin</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">n</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="2" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Ratio </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">with</content>
                                    <content styleCode="bold">/</content>
                                    <content styleCode="bold">without </content>
                                    <content styleCode="bold">azithromycin</content>
                                    <content styleCode="bold">) </content>
                                    <content styleCode="bold">of </content>
                                    <content styleCode="bold">Co</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">administered </content>
                                    <content styleCode="bold">Drug </content>
                                    <content styleCode="bold">Pharmacokinetic</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Parameters </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">90</content>
                                    <content styleCode="bold">% </content>
                                    <content styleCode="bold">CI</content>
                                    <content styleCode="bold">);</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">No </content>
                                    <content styleCode="bold">Effect </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">1</content>
                                    <content styleCode="bold">.</content>
                                    <content styleCode="bold">00</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Mean </content>
                                    <content styleCode="bold">C<sub>m</sub>
                                       <sub>a</sub>
                                       <sub>x</sub>
                                    </content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Mean </content>
                                    <content styleCode="bold">AUC</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Atorvastatin<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">10 mg/day for 8 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg/day orally on days 6 to 8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.83<br/>(0.63 to 1.08)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.01<br/>(0.81 to 1.25)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Carbamazepine<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">200 mg/day for 2 days, then 200 mg <br/>twice a day for 18 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg/day orally for days 16 to 18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.97 <br/>(0.88 to 1.06)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.96 <br/>(0.88 to 1.06)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Cetirizine<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">20 mg/day for 11 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg orally on day 7, then 250 mg/day <br/>on days 8 to 11<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">14<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.03 <br/>(0.93 to 1.14)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.02 <br/>(0.92 to 1.13)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Didanosine<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">200 mg orally twice a day for 21 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,200 mg/day orally on days 8 to 21<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.44 <br/>(0.85 to 2.43)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.14 <br/>(0.83 to 1.57)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Efavirenz<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">400 mg/day for 7 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">600 mg orally on day 7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">14<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.04<footnote ID="ID665_1">-90% Confidence interval not reported</footnote>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.95<footnoteRef IDREF="ID665_1"/>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Fluconazole<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">200 mg orally single dose<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,200 mg orally single dose<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.04 <br/>(0.98 to 1.11)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.01 <br/>(0.97 to 1.05)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Indinavir<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">800 mg three times a day for 5 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,200 mg orally on day 5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.96 <br/>(0.86 to 1.08)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.90 <br/>(0.81 to 1.00)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Midazolam<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">15 mg orally on day 3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg/day orally for 3 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.27 <br/>(0.89 to 1.81)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.26 <br/>(1.01 to 1.56)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Nelfinavir<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">750 mg three times a day for 11 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,200 mg orally on day 9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">14<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.90 <br/>(0.81 to 1.01)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.85 <br/>(0.78 to 0.93)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Sildenafil<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">100 mg on days 1 and 4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg/day orally for 3 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.16 <br/>(0.86 to 1.57)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.92 <br/>(0.75 to 1.12)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Theophylline<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4 mg/kg IV on days 1, 11, 25<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg orally on day 7, 250 mg/day <br/>on days 8 to 11<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">10<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.19 <br/>(1.02 to 1.40)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.02 <br/>(0.86 to 1.22)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Theophylline<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">300 mg orally BID ×15 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg orally on day 6, then 250 mg/day <br/>on days 7 to 10<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.09 <br/>(0.92 to 1.29)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.08 <br/>(0.89 to 1.31)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Triazolam<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.125 mg on day 2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg orally on day 1, then 250 mg/day <br/>on day 2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.06<footnoteRef IDREF="ID665_1"/>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.02<footnoteRef IDREF="ID665_1"/>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Trimethoprim/ Sulfamethoxazole<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">160 mg/800 mg/day orally for 7 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,200 mg orally on day 7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.85 <br/>(0.75 to 0.97)/ 0.90 <br/>(0.78 to 1.03)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.87 <br/>(0.80 to 0.95/<br/>0.96 <br/>(0.88 to 1.03)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Zidovudine<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg/day orally for 21 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">600 mg/day orally for 14 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.12 <br/>(0.42 to 3.02)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.94 <br/>(0.52 to 1.7)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Zidovudine<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">500 mg/day orally for 21 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,200 mg/day orally for 14 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.31<br/>(0.43 to 3.97)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.30<br/>(0.69 to 2.43)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="ID666" width="100%">
                           <caption>Table 2: Drug Interactions: Pharmacokinetic Parameters for Azithromycin in the Presence of Co-administered Drugs [see DRUG INTERACTIONS (<linkHtml href="#ID589">7.3</linkHtml>)]. </caption>
                           <col width="19%"/>
                           <col width="18%"/>
                           <col width="17%"/>
                           <col width="6%"/>
                           <col width="21%"/>
                           <col width="19%"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Co</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">administered </content>
                                    <content styleCode="bold">Drug</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Dose </content>
                                    <content styleCode="bold">of </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Co</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">administered </content>
                                    <content styleCode="bold">Drug</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Dose </content>
                                    <content styleCode="bold">of </content>
                                    <content styleCode="bold">Azithromycin</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">n</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="2" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Ratio </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">with</content>
                                    <content styleCode="bold">/</content>
                                    <content styleCode="bold">without</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">co</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">administered </content>
                                    <content styleCode="bold">drug</content>
                                    <content styleCode="bold">) </content>
                                    <content styleCode="bold">of</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">Pharmacokinetic </content>
                                    <content styleCode="bold">Parameters </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">90</content>
                                    <content styleCode="bold">% </content>
                                    <content styleCode="bold">CI</content>
                                    <content styleCode="bold">);</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">No </content>
                                    <content styleCode="bold">Effect </content>
                                    <content styleCode="bold">= </content>
                                    <content styleCode="bold">1</content>
                                    <content styleCode="bold">.</content>
                                    <content styleCode="bold">00</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Mean </content>
                                    <content styleCode="bold">C<sub>m</sub>
                                       <sub>a</sub>
                                       <sub>x</sub>
                                    </content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Mean </content>
                                    <content styleCode="bold">AUC</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Efavirenz<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">400 mg/day for 7 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">600 mg orally on day 7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">14<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.22 <br/>(1.04 to 1.42)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.92<footnote ID="ID666_1">-90% Confidence interval not reported</footnote>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Fluconazole<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">200 mg orally single dose<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,200 mg orally single dose<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.82 <br/>(0.66 to 1.02)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.07 <br/>(0.94 to 1.22)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Nelfinavir<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">750 mg three times a day for 11 days<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,200 mg orally on day 9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">14<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.36 <br/>(1.77 to 3.15)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.12 <br/>(1.80 to 2.50)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID621">
                     <id root="25c39305-b6bb-41c0-8c85-b7f73448807d"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph ID="ID622">
                           <content styleCode="bold">
                              <content styleCode="italics">Mechanism of Action </content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Resistance </content>
                           </content>
                        </paragraph>
                        <paragraph>The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often by methylation. Ribosomal modifications can determine cross resistance to other macrolides, lincosamides, and streptogramin B (MLS<sub>B</sub> phenotype). The mechanism of acquired mutational resistance in isolates of <content styleCode="italics">Mycobacterium avium </content>complex (i.e., 23S rRNA genemutation) is the same for both clarithromycin and azithromycin. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Antimicrobial Activity </content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin has been shown to be active against the following microorganisms, both <content styleCode="italics">in vitro </content>and in clinical infections. <content styleCode="italics">[see INDICATIONS AND USAGE (<linkHtml href="#ID522">1</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Mycobacteria </content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Mycobacterium avium </content>complex (MAC) consisting of: </paragraph>
                        <paragraph>
                           <content styleCode="italics">Mycobacterium avium</content> </paragraph>
                        <paragraph>
                           <content styleCode="italics">Mycobacterium intracellulare</content> </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Other Microorganisms </content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Chlamydia trachomatis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Susceptibility Testing </content>
                           </content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID631">
               <id root="f45e3e8f-4e97-49cf-8396-5d3436ba8643"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20221117"/>
               <component>
                  <section ID="ID632">
                     <id root="bf853dbd-c266-4641-aca1-b40922d899f8"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID633">Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse lymphoma assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. In fertility studies conducted in male and female rats, oral administration of azithromycin for 64 to 66 days (males) or 15 days (females) prior to and during cohabitation resulted in decreased pregnancy rate at 20 and 30 mg/kg/day when both males and females were treated with azithromycin. This minimal effect on pregnancy rate (approximately 12% reduction compared to concurrent controls) did not become more pronounced when the dose was increased from 20 to 30 mg/kg/day (approximately 0.3 to 0.5 times the adult human daily dose of 600 mg based on body surface area) and it was not observed when only one animal in the mated pair was treated. There were no effects on any other reproductive parameters, and there were no effects on fertility at 10 mg/kg/day. The relevance of these findings to patients being treated with azithromycin at the doses and durations recommended in the prescribing information is uncertain.</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID634">
                     <id root="f20047f2-d98e-455e-b043-606cd7dc890c"/>
                     <title>13.2 Animal Toxicology</title>
                     <text>
                        <paragraph ID="ID635">Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given multiple doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) in dogs and rats treated with azithromycin at doses which, expressed on the basis of body surface area, are similar to or less than the highest recommended adult human dose. This effect has been shown to be reversible after cessation of azithromycin treatment. Based on the pharmacokinetic data, phospholipidosis has been seen in the rat (50 mg/kg/day dose) at the observed maximal plasma concentration of 1.3 mcg/mL (1.6 times the observed C<sub>max</sub> of 0.821 mcg/mL at the adult dose of 2 g.) Similarly, it has been shown in the dog (10 mg/kg/day dose) at the observed maximal serum concentration of 1 mcg/mL (1.2 times the observed C<sub>max</sub> of 0.821 mcg/mL at the adult dose of 2 g). </paragraph>
                        <paragraph>Phospholipidosis was also observed in neonatal rats dosed for 18 days at 30 mg/kg/day, which is less than the pediatric dose of 60 mg/kg based on the surface area. It was not observed in neonatal rats treated for 10 days at 40 mg/kg/day with mean maximal serum concentrations of 1.86 mcg/mL, approximately 1.5 times the C<sub>max</sub> of 1.27 mcg/mL at the pediatric dose. Phospholipidosis has been observed in neonatal dogs (10 mg/kg/day) at maximum mean whole blood concentrations of 3.54 mcg/mL, approximately 3 times the pediatric dose C<sub>max</sub>.</paragraph>
                        <paragraph>The significance of the finding for animals and for humans is unknown. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID636">
               <id root="f0ea8744-3264-4615-9531-6a4f80937ca7"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20221117"/>
               <component>
                  <section ID="ID637">
                     <id root="26f024d3-18b8-473c-8a87-6315b65b23f7"/>
                     <title>14.1 Clinical Studies in Patients with Advanced HIV Infection for the Prevention and Treatment of Disease Due to Disseminated Mycobacterium avium Complex (MAC)</title>
                     <text>
                        <paragraph ID="ID638">
                           <content styleCode="italics">[see INDICATIONS AND USAGE (<linkHtml href="#ID522">1</linkHtml>)] </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Prevention of Disseminated MAC Disease</content>
                           </content>
                        </paragraph>
                        <paragraph>Two randomized, double<content styleCode="bold">-</content>blind clinical trials were performed in patients with CD4 counts   &lt;100 cells/µL. The first trial (Study 155) compared azithromycin (1200 mg once weekly) to placebo and enrolled 182 patients with a mean CD4 count of 35 cells/mcgL. The second trial (Study 174) randomized 723 patients to either azithromycin (1200 mg once weekly), rifabutin (300 mg daily), or the combination of both. The mean CD4 count was 51 cells/mcgL. The primary endpoint in these trials was disseminated MAC disease. Other endpoints included the incidence of clinically significant MAC disease and discontinuations from therapy for drug-related side effects. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">MAC bacteremia </content>
                           </content>
                        </paragraph>
                        <paragraph>In Study 155, 85 patients randomized to receive azithromycin and 89 patients randomized to receive placebo met the entrance criteria. Cumulative incidences at 6, 12, and 18 months of the possible outcomes are in the following table:</paragraph>
                        <table ID="ID671" width="99%">
                           <col width="17%"/>
                           <col width="26%"/>
                           <col width="13%"/>
                           <col width="26%"/>
                           <col width="17%"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" colspan="4" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Cumulative </content>
                                    <content styleCode="bold">Incidence </content>
                                    <content styleCode="bold">Rate</content>
                                    <content styleCode="bold">, </content>
                                    <content styleCode="bold">%: </content>
                                    <content styleCode="bold">Placebo </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">89</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Month</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC </content>
                                    <content styleCode="bold">Free </content>
                                    <content styleCode="bold">and </content>
                                    <content styleCode="bold">Alive</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Adverse </content>
                                    <content styleCode="bold">Experience</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Lost </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">Follow</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">up</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">69.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">13.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">10.1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">47.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">19.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">15.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18.0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">37.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">22.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18.0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">22.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" colspan="4" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Cumulative </content>
                                    <content styleCode="bold">Incidence </content>
                                    <content styleCode="bold">Rate</content>
                                    <content styleCode="bold">, </content>
                                    <content styleCode="bold">%: </content>
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">85</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Month</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC </content>
                                    <content styleCode="bold">Free </content>
                                    <content styleCode="bold">and </content>
                                    <content styleCode="bold">Alive</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Adverse </content>
                                    <content styleCode="bold">Experience</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Lost </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">Follow</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">up</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">84.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">9.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">63.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">8.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">16.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">11.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">44.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">11.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">25.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">17.6<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID640">The difference in the one-year cumulative incidence rates of disseminated MAC disease (placebo-azithromycin) is 10.9%. This difference is statistically significant (p=0.037) with a 95% confidence interval for this difference of 0.8%, 20.9%. The comparable number of patients experiencing adverse events and the fewer number of patients lost to follow-up on azithromycin should be taken into account when interpreting the significance of this difference.</paragraph>
                        <paragraph>In Study 174, 223 patients randomized to receive rifabutin, 223 patients randomized to receive azithromycin, and 218 patients randomized to receive both rifabutin and azithromycin met the entrance criteria. Cumulative incidences at 6, 12, and 18 months of the possible outcomes are recorded in the following table: </paragraph>
                        <table ID="ID672" width="100%">
                           <col width="15%"/>
                           <col width="28%"/>
                           <col width="12%"/>
                           <col width="24%"/>
                           <col width="21%"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" colspan="5" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Cumulative </content>
                                    <content styleCode="bold">Incidence </content>
                                    <content styleCode="bold">Rate</content>
                                    <content styleCode="bold">, </content>
                                    <content styleCode="bold">%: </content>
                                    <content styleCode="bold">Rifabutin </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">223</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Month</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC </content>
                                    <content styleCode="bold">Free </content>
                                    <content styleCode="bold">and </content>
                                    <content styleCode="bold">Alive</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Adverse </content>
                                    <content styleCode="bold">Experience</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Lost </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">Follow</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">up</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">83.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">7.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">8.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.3<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">60.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">15.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">16.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">8.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">40.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">21.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">24.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">13.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" colspan="5" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Cumulative </content>
                                    <content styleCode="bold">Incidence </content>
                                    <content styleCode="bold">Rate</content>
                                    <content styleCode="bold">, </content>
                                    <content styleCode="bold">%: </content>
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">223</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Month</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC </content>
                                    <content styleCode="bold">Free </content>
                                    <content styleCode="bold">and </content>
                                    <content styleCode="bold">Alive</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Adverse </content>
                                    <content styleCode="bold">Experience</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Lost </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">Follow</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">up</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">85.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5.4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">65.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">7.6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">16.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">10.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">45.3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">23.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" colspan="5" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Cumulative </content>
                                    <content styleCode="bold">Incidence </content>
                                    <content styleCode="bold">Rate</content>
                                    <content styleCode="bold">, </content>
                                    <content styleCode="bold">%: </content>
                                    <content styleCode="bold">Azithromycin</content>
                                    <content styleCode="bold">/</content>
                                    <content styleCode="bold">Rifabutin </content>
                                    <content styleCode="bold">Combination </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">n</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">218</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Month</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC </content>
                                    <content styleCode="bold">Free </content>
                                    <content styleCode="bold">and </content>
                                    <content styleCode="bold">Alive</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">MAC</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Adverse </content>
                                    <content styleCode="bold">Experience</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Lost </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">Follow</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">up</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">89.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.2<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">71.6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">15.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">10.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">18<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">49.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">29.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">15.1<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID642">Comparing the cumulative one<content styleCode="bold">-</content>year incidence rates, azithromycin monotherapy is at least as effective as rifabutin monotherapy. The difference (rifabutin – azithromycin) in the one<content styleCode="bold">-</content>year rates (7.6%) is statistically significant (p=0.022) with an adjusted 95% confidence interval (0.9%, 14.3%). Additionally, azithromycin/rifabutin combination therapy is more effective than rifabutin alone. The difference (rifabutin – azithromycin/rifabutin) in the cumulative one<content styleCode="bold">-</content>year incidence rates (12.5%) is statistically significant (p&lt;0.001) with an adjusted 95% confidence interval of 6.6%, 18.4%. The comparable number of patients experiencing adverse events and the fewer number of patients lost to follow-up on rifabutin should be taken into account when interpreting the significance of this difference. </paragraph>
                        <paragraph>In Study 174, sensitivity testing<sup>2</sup>was performed on all available MAC isolates from subjects randomized to either azithromycin, rifabutin, or the combination. The distribution of MIC values for azithromycin from susceptibility testing of the breakthrough isolates was similar between trial arms. As the efficacy of azithromycin in the treatment of disseminated MAC has not been established, the clinical relevance of these <content styleCode="italics">in vitro </content>MICs as an indicator of susceptibility or resistance is not known. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Clinically Significant Disseminated MAC Disease </content>
                           </content>
                        </paragraph>
                        <paragraph>In association with the decreased incidence of bacteremia, patients in the groups randomized to either azithromycin alone or azithromycin in combination with rifabutin showed reductions in the signs and symptoms of disseminated MAC disease, including fever or night sweats, weight loss, and anemia. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Discontinuations from Therapy for Drug-Related Side Effects </content>
                           </content>
                        </paragraph>
                        <paragraph>In Study 155, discontinuations for drug-related toxicity occurred in 8.2% of subjects treated with azithromycin and 2.3% of those given placebo (p=0.121). In Study 174, more subjects discontinued from the combination of azithromycin and rifabutin (22.7%) than from azithromycin alone (13.5%; p=0.026) or rifabutin alone (15.9%; p=0.209). </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Safety </content>
                           </content>
                        </paragraph>
                        <paragraph>As these patients with advanced HIV disease were taking multiple concomitant medications and experienced a variety of intercurrent illnesses, it was often difficult to attribute adverse reactions to study medication. Overall, the nature of adverse reactions seen on the weekly dosage regimen of azithromycin over a period of approximately one year in patients with advanced HIV disease were similar to that previously reported for shorter course therapies. </paragraph>
                        <table ID="ID673" width="99%">
                           <caption>INCIDENCE OF ONE OR MORE TREATMENT-RELATED<sup>a</sup>
                              <sup/>ADVERSE REACTIONS<sup>b</sup>
                              <sup/>IN HIV INFECTED PATIENTS RECEIVING PROPHYLAXIS FOR DISSEMINATED MAC OVER APPROXIMATELY 1 YEAR</caption>
                           <col width="26%"/>
                           <col width="9%"/>
                           <col width="16%"/>
                           <col width="15%"/>
                           <col width="17%"/>
                           <col width="16%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup>
                                       <sup/>Includes those reactions considered possibly or probably related to study drug <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup>
                                       <sup/>&gt;2% adverse reaction rates for any group (except uveitis) <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="6">
                                    <paragraph styleCode="Footnote">
                                       <br/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" colspan="1" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="2" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Study </content>
                                    <content styleCode="bold">155</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Lrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Botrule Toprule">
                                    <content styleCode="bold">Study </content>
                                    <content styleCode="bold">174</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" colspan="1" styleCode=" Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Placebo </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">91</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">1200 </content>
                                    <content styleCode="bold">mg </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">weekly </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">89</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">1200 </content>
                                    <content styleCode="bold">mg </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">weekly </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">233</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Rifabutin </content>
                                    <content styleCode="bold">300 </content>
                                    <content styleCode="bold">mg </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">daily </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">236</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">+ </content>
                                    <content styleCode="bold">Rifabutin </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">224</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Mean Duration of Therapy (days)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">303.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">402.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">315<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">296.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">344.4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Discontinuation of Therapy<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">8.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">13.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">15.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">22.7<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Autonomic </content>
                                    <content styleCode="bold">Nervous </content>
                                    <content styleCode="bold">System</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Mouth Dry<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.7<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Central </content>
                                    <content styleCode="bold">Nervous </content>
                                    <content styleCode="bold">System</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Dizziness<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Headache<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4.5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Gastrointestinal</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Diarrhea<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">15.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">52.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">50.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">19.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">50.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Loose Stools<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6.6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">19.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">9.4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Abdominal Pain<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6.6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">27<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">32.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12.3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">31.7<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Dyspepsia<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Flatulence<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">10.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Nausea<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">11<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">32.6<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">27<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">16.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">28.1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Vomiting<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">6.7<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.8<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">General</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Fever<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Fatigue<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Malaise<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.2<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Musculoskeletal</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Arthralgia<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">7.1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Psychiatric</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Anorexia<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Skin </content>
                                    <content styleCode="bold">&amp; </content>
                                    <content styleCode="bold">Appendages</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Pruritus<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">7.6<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Rash<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">8.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">9.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">11.1<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Skin discoloration<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.2<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Special </content>
                                    <content styleCode="bold">Senses</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Tinnitus<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">4.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">3.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.9<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Hearing Decreased<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.2<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.1<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.9<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Uveitis<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0.4<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Taste Perversion<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.3<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">2.5<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1.3<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID644">Adverse reactions related to the gastrointestinal tract were seen more frequently in patients receiving azithromycin than in those receiving placebo or rifabutin. In Study 174, 86% of diarrheal episodes were mild to moderate in nature with discontinuation of therapy for this reason occurring in only 9/233 (3.8%) of patients. </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Changes in Laboratory Values </content>
                           </content>
                        </paragraph>
                        <paragraph>In these immunocompromised patients with advanced HIV infection, it was necessary to assess laboratory abnormalities developing on trial with additional criteria if baseline values were outside the relevant normal range. </paragraph>
                        <table ID="ID674" width="100%">
                           <caption>PROPHYLAXIS AGAINST DISSEMINATED MAC ABNORMAL LABORATORY VALUES<sup>a</sup>
                           </caption>
                           <col width="19%"/>
                           <col width="22%"/>
                           <col width="8%"/>
                           <col width="7%"/>
                           <col width="8%"/>
                           <col width="7%"/>
                           <col width="8%"/>
                           <col width="6%"/>
                           <col width="8%"/>
                           <col width="7%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="10">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup>excludes subjects outside of the relevant normal range at baseline<br/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top" colspan="2" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" colspan="2" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" colspan="2" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">1200 </content>
                                    <content styleCode="bold">mg </content>
                                    <content styleCode="bold">weekly</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" colspan="2" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Rifabutin </content>
                                    <content styleCode="bold">300 </content>
                                    <content styleCode="bold">mg </content>
                                    <content styleCode="bold">daily</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" colspan="2" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">&amp; </content>
                                    <content styleCode="bold">Rifabutin</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule Toprule">Hemoglobin <br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Rrule Toprule">&lt;8 g/dL<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">1/51 <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">4/170<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">4/114<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">4%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">8/107<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">8%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule">Platelet Count<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Rrule">&lt;50 × 10<sup>3</sup>/mm<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">1/71 <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">1%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">4/260<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">2/182<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">1%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">6/181<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule">WBC Count<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Rrule">&lt;1 × 10<sup>3</sup>/mm<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">0/8 <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">0%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">2/70<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">3%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">2/47<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">4%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">0/43<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">0%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule">Neutrophils <br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Rrule">&lt;500/mm<sup>3</sup>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">0/26 <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">0%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">4/106<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">4%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">3/82<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">4%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">2/78<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule">SGOT<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Rrule">&gt;5 × ULN<footnote ID="ID674_1">Upper Limit of Normal</footnote>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">1/41 <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">8/158<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">5%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">3/121<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">3%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">6/114<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">5%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule">SGPT<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Rrule">&gt;5 × ULN<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">0/49 <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">0%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">8/166<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">5%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">3/130<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">5/117<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">4%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule Botrule">Alk Phos<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Rrule Botrule">&gt;5 × ULN<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">1/80 <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">1%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">4/247<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">2/172<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">1%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Lrule Botrule Toprule">3/164<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Rrule Botrule Toprule">2%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID646">
                           <content styleCode="bold">
                              <content styleCode="italics">Treatment of Disseminated MAC Disease</content>
                           </content>
                        </paragraph>
                        <paragraph>One randomized, double<content styleCode="bold">-</content>blind clinical trial (Study 189) was performed in patients with disseminated MAC.  In this trial, 246 HIV<content styleCode="bold">-</content>infected patients with disseminated MAC received either azithromycin 250 mg daily (N=65), azithromycin 600 mg daily (N=91), or clarithromycin 500 mg twice a day (N=90), each administered with ethambutol 15 mg/kg daily, for 24 weeks. Blood cultures and clinical assessments were performed every 3 weeks through week 12 and monthly thereafter through week 24.  After week 24, patients were switched to any open<content styleCode="bold">-</content>label therapy at the discretion of the investigator and followed every 3 months through the last follow<content styleCode="bold">-</content>up visit of the trial.  Patients were followed from the baseline visit for a period of up to 3.7 years (median: 9 months). MAC isolates recovered during treatment or post-treatment were obtained whenever possible. </paragraph>
                        <paragraph>The primary endpoint was sterilization by week 24.  Sterilization was based on data from the central laboratory, and was defined as two consecutive observed negative blood cultures for MAC, independent of missing culture data between the two negative observations. Analyses were performed on all randomized patients who had a positive baseline culture for MAC. </paragraph>
                        <paragraph>The azithromycin 250 mg arm was discontinued after an interim analysis at 12 weeks showed a significantly lower clearance of bacteremia compared to clarithromycin 500 mg twice a day. Efficacy results for the azithromycin 600 mg daily and clarithromycin 500 mg twice a day treatment regimens are described in the following table: </paragraph>
                        <table ID="ID675" width="100%">
                           <col width="35%"/>
                           <col width="23%"/>
                           <col width="25%"/>
                           <col width="17%"/>
                           <tbody>
                              <tr>
                                 <td align="center" valign="middle" colspan="4" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">RESPONSE </content>
                                    <content styleCode="bold">TO </content>
                                    <content styleCode="bold">THERAPY </content>
                                    <content styleCode="bold">OF </content>
                                    <content styleCode="bold">PATIENTS </content>
                                    <content styleCode="bold">TAKING </content>
                                    <content styleCode="bold">ETHAMBUTOL </content>
                                    <content styleCode="bold">AND</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">EITHER </content>
                                    <content styleCode="bold">AZITHROMYCIN </content>
                                    <content styleCode="bold">600 </content>
                                    <content styleCode="bold">MG </content>
                                    <content styleCode="bold">DAILY </content>
                                    <content styleCode="bold">OR </content>
                                    <content styleCode="bold">CLARITHROMYCIN </content>
                                    <content styleCode="bold">500 </content>
                                    <content styleCode="bold">MG </content>
                                    <content styleCode="bold">TWICE </content>
                                    <content styleCode="bold">A </content>
                                    <content styleCode="bold">DAY</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">600 </content>
                                    <content styleCode="bold">mg </content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold">daily</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Clarithromycin </content>
                                    <content styleCode="bold">500 </content>
                                    <content styleCode="bold">mg</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">twice </content>
                                    <content styleCode="bold">a </content>
                                    <content styleCode="bold">day</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">
                                       <footnote ID="ID675_1">[95% confidence interval] on difference in rates (azithromycin-clarithromycin)</footnote>95</content>
                                    <content styleCode="bold">.</content>
                                    <content styleCode="bold">1</content>
                                    <content styleCode="bold">% </content>
                                    <content styleCode="bold">CI </content>
                                    <content styleCode="bold">on</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">difference</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Patients with positive culture <br/>at baseline<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">68<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">57<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">    Week 24<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Two consecutive negative <br/>blood cultures<footnote ID="ID675_2">Primary endpoint</footnote>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">31/68 (46%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">32/57 (56%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">[-28, 7]<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">Mortality<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">16/68 (24%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">15/57 (26%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">[-18, 13]<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID648">The primary endpoint, rate of sterilization of blood cultures (two consecutive negative cultures) at 24 weeks, was lower in the azithromycin 600 mg daily group than in the clarithromycin 500 mg twice a day group.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Sterilization by Baseline Colony Count </content>
                           </content>
                        </paragraph>
                        <paragraph>Within both treatment groups, the sterilization rates at week 24 decreased as the range of MAC cfu/mL increased.</paragraph>
                        <table ID="ID676" width="100%">
                           <col width="30%"/>
                           <col width="36%"/>
                           <col width="34%"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Azithromycin </content>
                                    <content styleCode="bold">600 </content>
                                    <content styleCode="bold">mg </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">68</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">Clarithromycin </content>
                                    <content styleCode="bold">500 </content>
                                    <content styleCode="bold">mg </content>
                                    <content styleCode="bold">twice </content>
                                    <content styleCode="bold">a </content>
                                    <content styleCode="bold">day</content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">=</content>
                                    <content styleCode="bold">57</content>
                                    <content styleCode="bold">)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">groups </content>
                                    <content styleCode="bold">stratified </content>
                                    <content styleCode="bold">by </content>
                                    <content styleCode="bold">MAC </content>
                                    <content styleCode="bold">colony </content>
                                    <content styleCode="bold">counts </content>
                                    <content styleCode="bold">at </content>
                                    <content styleCode="bold">baseline</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">no</content>
                                    <content styleCode="bold">. </content>
                                    <content styleCode="bold">(%) </content>
                                    <content styleCode="bold">subjects </content>
                                    <content styleCode="bold">in </content>
                                    <content styleCode="bold">stratified </content>
                                    <content styleCode="bold">group </content>
                                    <content styleCode="bold">sterile </content>
                                    <content styleCode="bold">at </content>
                                    <content styleCode="bold">week </content>
                                    <content styleCode="bold">24</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">
                                    <content styleCode="bold">no</content>
                                    <content styleCode="bold">. </content>
                                    <content styleCode="bold">(%) </content>
                                    <content styleCode="bold">subjects </content>
                                    <content styleCode="bold">in </content>
                                    <content styleCode="bold">stratified </content>
                                    <content styleCode="bold">group </content>
                                    <content styleCode="bold">sterile </content>
                                    <content styleCode="bold">at </content>
                                    <content styleCode="bold">week </content>
                                    <content styleCode="bold">24</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">≤10 cfu/mL<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">10/15 (66.7%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">12/17 (70.6%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">11 to 100 cfu/mL<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">13/28 (46.4%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">13/19 (68.4%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">101 to 1,000 cfu/mL<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">7/19 (36.8%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">5/13 (38.5%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1,001 to 10,000 cfu/mL<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1/5 (20.0%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1/5 (20%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">&gt;10,000 cfu/mL<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">0/1 (0.0%)<br/>
                                 </td>
                                 <td align="center" valign="middle" styleCode=" Lrule Rrule Botrule Toprule">1/3 (33.3%)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID650">
                           <content styleCode="bold">
                              <content styleCode="italics">Susceptibility Pattern of MAC Isolates </content>
                           </content>
                        </paragraph>
                        <paragraph>Susceptibility testing was performed on MAC isolates recovered at baseline, at the time of breakthrough on therapy or during post-therapy follow-up.  The T100 radiometric broth method was employed to determine azithromycin and clarithromycin MIC values. Azithromycin MIC values ranged from &lt;4 to &gt;256 mcg/mL and clarithromycin MICs ranged from &lt;1 to &gt;32 mcg/mL. The individual MAC susceptibility results demonstrated that azithromycin MIC values could be 4 to 32-fold higher than clarithromycin MIC values. </paragraph>
                        <paragraph>During treatment and post-treatment follow-up for up to 3.7 years (median: 9 months) in Study 189, a total of 6/68 (9%) and 6/57 (11%) of the patients randomized to azithromycin 600 mg daily and clarithromycin 500 mg twice a day respectively, developed MAC blood culture isolates that had a sharp increase in MIC values.  All twelve MAC isolates had azithromycin MICs ≥256 mcg/mL and clarithromycin MICs &gt;32 mcg/mL. These high MIC values suggest development of drug resistance. However, at this time, specific breakpoints for separating susceptible and resistant MAC isolates have not been established for either macrolide. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID651">
               <id root="83d2b61f-0e2b-41f9-901d-4618477defde"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <effectiveTime value="20221117"/>
               <component>
                  <section ID="ID677">
                     <id root="8405fb30-a6c4-45a8-b7b0-169dfb81a846"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="ordered" ID="ID688">
                           <item>Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard, CLSI document M24 A2, CLSI, 2011.</item>
                           <item>Griffith DE, Aksamit T, Brown-Elliot BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. <content styleCode="italics">Am J Respir Crit Care Med. </content>2007; 175:367-416.</item>
                        </list>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID653">
               <id root="b5283852-cb7c-4ea9-99af-abb2fda2ea54"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20221117"/>
               <component>
                  <section ID="ID654">
                     <id root="703227fa-a6e5-4a1f-9c41-c7779ff16e09"/>
                     <text>
                        <paragraph ID="ID655">Azithromycin Tablets USP, 600 mg are supplied as white, oval shaped film-coated tablets, engraved with "LU" on one side and "L06" on the other side containing azithromycin dihydrate equivalent to 600 mg of azithromycin USP.</paragraph>
                        <paragraph>These are packaged in bottles of 30 tablets as follows:</paragraph>
                        <paragraph>Bottles of 30 Tablets:   NDC 68180-863-06</paragraph>
                        <paragraph>Tablets should be stored at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID656">
               <id root="3c95d707-294d-4a04-a167-bbe96d50c72e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250218"/>
               <component>
                  <section ID="ID678">
                     <id root="9c655966-7453-4ef2-bfba-f76debb18eaa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID657">Azithromycin tablets may be taken with or without food. However, increased tolerability has been observed when tablets are taken with food. </paragraph>
                        <paragraph>Patients should also be cautioned not to take aluminum- and magnesium-containing antacids and azithromycin simultaneously. </paragraph>
                        <paragraph>The patient should be directed to discontinue azithromycin immediately and contact a physician if any signs of an allergic reaction occur. </paragraph>
                        <paragraph>Direct parents or caregivers to contact their physician if vomiting and irritability with feeding occurs in the infant.</paragraph>
                        <paragraph>Patients should be counseled that antibacterial drugs, including azithromycin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When azithromycin is prescribed to treat bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by azithromycin or other antibacterial drugs in the future. </paragraph>
                        <paragraph>Diarrhea is a common problem caused by antibacterial which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial.  If this occurs, patients should contact their physician as soon as possible. </paragraph>
                     </text>
                     <effectiveTime value="20221117"/>
                  </section>
               </component>
               <component>
                  <section ID="ID658">
                     <id root="c50e4278-5d30-4393-bb40-e3b43d03fd79"/>
                     <text>
                        <paragraph ID="ID659">LUPIN and the  <renderMultiMedia referencedObject="IMGID6591"/>  are registered trademarks of Lupin Pharmaceuticals, Inc.</paragraph>
                        <paragraph>Manufactured for:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                        </paragraph>
                        <paragraph>Naples, FL 34108</paragraph>
                        <paragraph>United States</paragraph>
                        <paragraph>Manufactured by:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Lupin Limited</content>
                        </paragraph>
                        <paragraph>Goa - 403722</paragraph>
                        <paragraph>India</paragraph>
                        <paragraph>Revised: October 2024                                                                                  ID#: 276179</paragraph>
                     </text>
                     <effectiveTime value="20250218"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="IMGID6591">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="821a327e-282e-411a-9c3f-0866e90f05af-659-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID660">
               <id root="bbd7f040-9355-49a8-9bb3-5ecdd19ef3f7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <effectiveTime value="20250218"/>
               <component>
                  <section ID="ID661">
                     <id root="1e7cd085-bde3-43ff-88ce-584524d59e33"/>
                     <text>
                        <paragraph ID="ID662">Azithromycin Tablets USP, 600 mg</paragraph>
                        <paragraph>30 Tablets- Container Label</paragraph>
                        <paragraph>NDC 68180-863-06</paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                     </text>
                     <effectiveTime value="20250218"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Bottle Label - 600 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="821a327e-282e-411a-9c3f-0866e90f05af-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>